Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

MERS, dMAb, HPV, Cancer vaccine, EP patents granted
DNA antibody constructs for use against middle east respiratory syndrome coronavirus
Patent number: 11230592
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.
Type: Grant
Filed: September 27, 2018
Date of Patent: January 25, 2022
Assignees: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, INOVIO PHARMACEUTICALS, INC.
Inventors: David Weiner, Trevor R F Smith, Kar Muthumani

DNA antibody constructs and method of using same
Patent number: 11208470
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
Type: Grant
Filed: September 26, 2018
Date of Patent: December 28, 2021
Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors: David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai

TUMOR-SPECIFIC NEOANTIGENS AND METHODS OF USING THE SAME
Publication number: 20210361755
Abstract: The disclosure relates to methods of manufacturing individualized vaccines that comprise nucleic acid molecules that encode one or more neoantigens specific for antigens that are expressed by a tumor in a subject. Compositions comprising coding regions encoding neoantigens organized in a pattern of nucleic acid sequences are also disclosed as well as methods of immunizing a subject using the same.
Type: Application
Filed: May 28, 2019
Publication date: November 25, 2021
Applicants: THE WISTAR INSTITUTE, INOVIO PHARMACEUTICALS, INC., GENEOS THERAPEUTICS, INC.
Inventors: Elizabeth Kennedy Duperret, Alfredo Perales Puchalt, David Weiner, Niranjan Y. Sardesai

Cancer vaccines targeting BORIS and uses thereof
Patent number: 11154601
Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.
Type: Grant
Filed: December 13, 2018
Date of Patent: October 26, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch

Cancer vaccines targeting mesothelin and uses thereof
Patent number: 11154602
Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.
Type: Grant
Filed: December 13, 2018
Date of Patent: October 26, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch

MERS-CoV vaccine
Patent number: 11135284
Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
Type: Grant
Filed: February 4, 2020
Date of Patent: October 5, 2021
Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai

Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
Patent number: 11124545
Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.
Type: Grant
Filed: May 20, 2019
Date of Patent: September 21, 2021
Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
Patent number: 11116838
Abstract: Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.
Type: Grant
Filed: January 28, 2016
Date of Patent: September 14, 2021
Assignees: The Trustees of the University of Pennsylvania, INOVIO PHARMACEUTICALS, INC.
Inventors: David Weiner, Karuppiah Muthumani, Niranjan Sardesai

Multiple tissue layer electroporation applicator and device
Patent number: 11097099
Abstract: The present invention relates to dual depth electroporation devices capable of electorporating both muscle tissue and skin tissue in a single application in order to generate a broad immune response in a subject, and uses of the same.
Type: Grant
Filed: March 1, 2011
Date of Patent: August 24, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventors: Kate Broderick, Feng Lin, Jay McCoy, Stephen V Kemmerrer, Rune Kjeken
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
Patent number: 11091518
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.
Type: Grant
Filed: May 5, 2017
Date of Patent: August 17, 2021
Assignees: The Trustees of the University of Pennsylvania, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Inovio Pharmaceuticals, Inc.
Inventors: David B. Weiner, Ami Patel, Jian Yan

Electroporation device with detachable needle array with lock-out system
Patent number: 11071859
Abstract: An electroporation device with a needle array removably attached thereto, the needle array having a body, a shroud movable with respect to the body between a rest position and one or more actuated positions, and an auto-lock assembly. Where the auto-lock assembly is adjustable between a locked configuration, where the shroud is not movable with respect to the body, and an unlocked configuration, where the shroud is movable with respect to the body, and where biasing the shroud from the rest position to the one or more actuated positions and back to the rest position adjusts the auto-lock from the unlocked configuration to the locked configuration.
Type: Grant
Filed: December 30, 2016
Date of Patent: July 27, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventors: Beat Stadelmann, Stephen Kemmerrer, Alejandro Campillo-Agusti, Eduardo Ho, Nathan Lovell, Steven Masterson

Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
Patent number: 11045535
Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
Type: Grant
Filed: January 31, 2018
Date of Patent: June 29, 2021
Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors: David Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan

Intradermal jet injection electroporation device
Patent number: 11027071
Abstract: An jet injection and electroporation device for use with an agent cartridge defining a volume containing a pre-measured dose of agent therein, the electroporation device including a housing having an axis extend therethrough, a nozzle at least partially positioned within the housing, and a cavity sized to receive at least a portion of the agent cartridge therein. The device also includes an array having a plurality of electrodes extending therefrom, a propulsion cartridge configured to operatively engage the cartridge when the agent cartridge is positioned within the cavity; and a power supply in electrical communication with the array.
Type: Grant
Filed: December 28, 2016
Date of Patent: June 8, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventors: Jay McCoy, Kate Broderick, Stephen Kemmerrer

Vaccines having an antigen and interleukin-21 as an adjuvant
Patent number: 11007265
Abstract: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
Type: Grant
Filed: November 6, 2018
Date of Patent: May 18, 2021
Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
Inventors: David B. Weiner, Matthew P. Morrow

Cancer vaccines and methods of treatment using the same
Patent number: 11007255
Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.
Type: Grant
Filed: February 3, 2017
Date of Patent: May 18, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventor: Jian Yan
Vaccines with interleukin-33 as an adjuvant
Patent number: 10933130
Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.
Type: Grant
Filed: August 30, 2018
Date of Patent: March 2, 2021
Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan

Vaccines with CD40 ligand as an adjuvant
Patent number: 10925961
Abstract: Disclosed herein is a vaccine comprising an antigen and CD40L. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
Type: Grant
Filed: March 18, 2016
Date of Patent: February 23, 2021
Assignees: The Trustees of the University of Pennsylvania, INOVIO PHARMACEUTICALS. INC.
Inventors: David Weiner, Matthew Morrow, Megan Wise

Vaccines for human papilloma virus and methods for using the same
Patent number: 10905755
Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.
Type: Grant
Filed: March 11, 2019
Date of Patent: February 2, 2021
Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors: David Weiner, Jian Yan

Oral mucosal electroporation device and use thereof
Patent number: 10905870
Abstract: The present invention relates to electroporation (EP) devices that are able to generate an electroporation causing electrical field at the mucosal layer, and preferably in a tolerable manner. Further, it includes the generation of a protective immune response, cellular and/or humoral, using the oral EP device along with a genetic construct that encodes an immunogenic sequence.
Type: Grant
Filed: November 12, 2018
Date of Patent: February 2, 2021
Assignee: Inovio Pharmaceuticals, Inc.
Inventors: Stephen V. Kemmerrer, Kate Broderick, Jay McCoy
https://patents.justia.com/assignee/inovio-pharmaceuticals-inc